Astellas Terminates First-in-Human Trial of ASP5502 in Sjögren's Syndrome

Astellas Pharma (Japan) has terminated its Phase I clinical trial of ASP5502, an oral small-molecule STING (Stimulator of Interferon Genes) inhibitor, in healthy adults and patients with primary Sjögren's syndrome. The clinical trial terminated before completion, according to an updated record on ClinicalTrials.gov (NCT06544642), with the status verified as of March 2026. The study, which began enrolling participants in August 2024 at a Fortrea Clinical Research Unit in Daytona Beach, Florida, had been designed as a first-in-human evaluation of the compound. No results have been posted to the registry.

What the Trial Was Designed to Evaluate

The study was a randomized, double-masked, placebo-controlled, sequential-dose Phase I trial structured in three parts. Part 1 enrolled healthy volunteers in single ascending dose cohorts, including a food-effect cohort to assess whether oral bioavailability changed under fed versus fasting conditions. Part 2 administered multiple ascending doses of ASP5502 or placebo to healthy volunteers once daily for 14 days. Part 3 was designed to administer repeated daily doses of ASP5502 — without a placebo comparator — to adults diagnosed with primary Sjögren's syndrome for 28 days, with dose levels informed by safety and pharmacokinetic data from the earlier parts.

The trial planned to enroll 116 participants aged 18 to 65. Primary endpoints centered on safety and tolerability: the number of participants with adverse events, laboratory value abnormalities, vital sign abnormalities, and 12-lead ECG abnormalities, measured up to Day 58. Secondary endpoints included standard pharmacokinetic parameters — Cmax, AUC, and trough concentrations — as well as concentration-QT analysis to assess cardiac safety. The trial also included biomarker response assessments, though specific biomarkers were not detailed in the registry record.

Eligibility for the Sjögren's syndrome cohort required a diagnosis established at least six months prior to enrollment, based on the 2016 ACR-EULAR classification criteria. Patients on immunosuppressant therapy, B-cell depleting agents, JAK inhibitors, calcineurin inhibitors, or corticosteroids exceeding 10 mg prednisone equivalents daily were excluded, as were those with secondary Sjögren's syndrome or other systemic autoimmune conditions.

Reason for Clinical Trial Termination

The registry listing does not specify a reason for the clinical trial status change from recruiting to terminated. However, based on tracking data compiled from the LARVOL DELTA database and reviewed in the context of Astellas's broader pipeline communications, the termination reflects a company strategic decision rather than a response to safety signals or efficacy failure. The trial's completion date was moved forward from July 2027 to March 2026, and enrollment reached 116 participants — short of the planned 132 — before the study was stopped. No safety or efficacy data have been disclosed publicly, and the registry confirms that no results have been posted.

The absence of a data safety monitoring board for this trial is consistent with its early-phase, dose-finding design, though it also means there is no independent body whose findings might contextualize the decision. The company has not issued a public statement elaborating on clinical trial termination reasons for this specific program.

Pipeline Context and Strategic Rationale

ASP5502 was positioned within Astellas's immune homeostasis research area, which sits outside the company's four declared primary focus areas: immuno-oncology, targeted protein degradation, genetic regulation, and blindness and regeneration. This classification placed the compound at the periphery of Astellas's stated strategic priorities.

Astellas has been executing a systematic drug development pipeline update over the past two years, driven in large part by the approaching patent cliff for enzalutamide (Xtandi), its largest revenue-generating product, with generic competition expected around 2027. The company has concentrated resources on late-stage oncology assets — enfortumab vedotin (Padcev), zolbetuximab (Vyloy), and several degrader and antibody-drug conjugate programs — while pruning early-stage assets in non-core therapeutic areas. Prior discontinuations include a CAR-T program derived from the Xyphos acquisition and a KRAS G12D pancreatic cancer program (ASP4396), with the company recording approximately ¥12.8 billion in discontinuation-related losses.

A February 2025 management restructuring created a new Chief R&D Officer role consolidating oversight of research and development divisions, a move interpreted as tightening portfolio governance. In this context, the termination of a first-in-human compound in an indication outside the company's core focus areas follows a pattern of resource reallocation toward programs with higher strategic priority and more advanced clinical data packages.

No other active clinical trials for ASP5502 are listed on ClinicalTrials.gov, and the AllSci database does not index additional studies for this compound. The termination appears to end clinical development of ASP5502 entirely, though Astellas has not confirmed this publicly.

The Sjögren's Syndrome Landscape

Primary Sjögren's syndrome affects an estimated 0.5 to 1.0% of the adult population, predominantly women, and is characterized by lymphocytic infiltration of exocrine glands leading to sicca symptoms — dry eyes and dry mouth — along with systemic manifestations including fatigue, arthralgia, and organ involvement. Despite its prevalence and burden, no therapy has received FDA approval specifically for the treatment of primary Sjögren's syndrome. Current management relies on symptomatic relief and off-label use of immunosuppressants.

The therapeutic landscape has seen repeated clinical failures. Bristol Myers Squibb's abatacept did not meet its primary endpoint in a Phase III trial. Novartis tested ianalumab (an anti-BAFF receptor antibody) and reported mixed results, though development continues. GSK's belimumab, approved for lupus, has been explored in Sjögren's syndrome without regulatory success in that indication. Horizon Therapeutics (now Amgen) evaluated teprotumumab but in a different autoimmune context. The BAFF/APRIL axis, B-cell depletion, and T-cell co-stimulation blockade have all been pursued with limited translational success in this disease.

STING inhibition represented a mechanistically distinct approach. The STING pathway, part of the innate immune system's cytosolic DNA sensing machinery, has been implicated in the pathogenesis of several autoimmune conditions, including Sjögren's syndrome, where aberrant type I interferon signaling is a recognized feature. Preclinical rationale for targeting STING in Sjögren's syndrome rests on the observation that chronic activation of the interferon pathway contributes to glandular inflammation and tissue damage. However, translating STING pathway modulation into clinical benefit in autoimmune disease remains unproven, and ASP5502 was among the first oral STING inhibitors to enter human testing for this indication.

The difficulty of the indication is reflected in the broader pattern of terminated clinical trials across multiple mechanisms and sponsors. Sjögren's syndrome presents particular challenges for drug development: heterogeneous patient populations, lack of validated surrogate endpoints, slow disease progression that complicates trial design, and incomplete understanding of which molecular pathways drive which clinical manifestations. The 2016 ACR-EULAR classification criteria improved diagnostic standardization, but translating classification into treatment stratification remains an open problem.

What Remains Unclear

Several questions remain unanswered by the available data. The registry does not disclose whether any participants in the Sjögren's syndrome cohort (Part 3) were dosed before termination, or whether the study was halted during the healthy volunteer dose-escalation phase. The pharmacokinetic and biomarker data collected during the trial, even if incomplete, could inform future STING inhibitor programs, but Astellas has not indicated whether these data will be published or shared.

The broader question — whether STING inhibition has therapeutic potential in primary Sjögren's syndrome — remains open. The termination of ASP5502 for strategic rather than scientific reasons means the hypothesis has neither been validated nor refuted by clinical data. Other companies exploring innate immune pathway modulation in autoimmune disease may draw limited conclusions from this company strategic decision trial outcome, given the absence of disclosed findings.

For Astellas, the termination is consistent with a disciplined approach to portfolio management under financial pressure, but it also narrows the company's presence in immunology at a time when the field is generating renewed interest from larger competitors investing in next-generation autoimmune therapies.

---

Spot something wrong? Report an issue with this article